The majority of lymphoblastic (precursor cell) neoplasms presents as leukemias. Consequently, the guidelines for lineage determination and subtyping of precursor cell neoplasms were primarily established for flow cytometry methods. Largescale studies of nonleukemic lymphoblastic lymphomas are lacking so far. We analyzed a large series of pediatric patients with lymphoblastic lymphoma treated within a prospective randomized trial (the Euro-LB 02 study). Among 193 lymphomas, in which a detailed immunohistochemical analysis was carried out, there were several unusual and diagnostically challenging morphologic and immunophenotypical variants. These included 11 lymphomas with mixed phenotypes expressing markers of at least 2 hematopoietic lineages, 7 terminal deoxynucleotide transferase-negative lymphoblastic lymphomas, and 3 undifferentiated hematopoietic neoplasms that could not be assigned to any lineage with certainty. Our data indicate that World Health Organzation guidelines for lineage determination and subtyping of precursor cell leukemia need to be adapted before they can be applied to immunohistochemical diagnosis of lymphoma. Using the experience from this cohort we suggest a resource-saving diagnostic staining panel for the immunohistochemical analysis of precursor cell neoplasms in formalin-fixed paraffin-embedded tissue.
L ymphoblastic (precursor) lymphoma is the second most common type of non-Hodgkin lymphoma in children and adolescents in Western Europe. 6 It derives from immature precursor lymphoblasts whose differentiation is arrested at early stages of maturation. Treatment trials in children and adolescents subdivide lymphoblastic neoplasms into 2 diseases: acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). 19 There is an ongoing discussion as to whether LBL and ALL are 2 distinct entities or whether they represent 2 variants of the same disease and the distinction is arbitrary. 6 The extent of blast infiltration of the bone marrow is currently used to distinguish between the 2 diseases, with 25% of tumor cells in the smears as an arbitrarily chosen cutoff. 26 LBL frequently presents as a mediastinal tumor in patients who are often critically ill but have little or no bone marrow infiltration. 19 Thus, diagnostic material obtained in cases of LBL is often limited to small specimens. Consequently, most of our knowledge about lymphoblastic neoplasms derives from cases of ALL, and the number of studies on LBL is limited. 6, 8, 11, [16] [17] [18] 22 This situation is reflected in the World Health Organization (WHO) 2008 classification, which refines the diagnostic criteria for precursor cell neoplasms in a manner that might pose a problem for pathologists who have to deal with tissue biopsy specimens without access to multicolor flow cytometry (FC). 26 This study represents the largest published series of LBL cases characterized by immunophenotyping. All samples were obtained during a prospectively randomized clinical trial for children and young adults under the age of 21 years (the Euro-LB 02 study). The analysis was carried out on formalin-fixed paraffin-embedded material (FFPE), and its purpose was to define the immunophenotype of LBL in children. The diagnostic staining approach for LBL recommended here was developed for use on FFPE specimens and for widespread application, including general pathology laboratories, and is intended as a step-wise and material-sparing diagnostic process. Thus, this is not a competing but a complementary concept to that of the WHO.
MATERIALS AND METHODS

Patients and Materials
The patient cohort was recruited in a prospective randomized trial, the Euro-LB 02 study (Euro-LB 02 treatment protocol for LBLs of the European Intergroup Cooperation on Childhood Non-Hodgkin Lymphoma International Multicentre Therapy Study Group), which included patients suffering from LBL who were aged 21 years and younger. According to current criteria, patients with LBL had <25% blasts in the bone marrow smears.
During the time of recruitment (2002 to 2008), patients were registered by 8 participating study groups from 14 European countries. All cases in which the initial diagnosis was made on tissue biopsy specimens (n = 279) were identified by the international database at the NHL-BFM study center in Giessen, Germany. Of these, the national reference pathologists were able to collect 196 for review. In 83 patients, no reference pathology review was possible because the diagnosis had been based on liquid material rather than a tissue biopsy (n = 8), because of a lack of access to the biopsy material for central review (n = 70) or insufficient material for appropriate review (n = 5).
Pathology Review and Immunophenotype
Selected cases were reviewed by the panel of national reference pathologists with a multiheaded microscope, including all challenging cases [Terminal deoxynucleotide transferase (TdT)-negative, ambiguous lineage, unusual morphology, staining difficult to interpret, low-quality specimen]. In addition, randomly chosen cases from every participating study group were reviewed to ensure that the quality of the immunohistochemical (IHC) staining and interpretation adhered to the defined standards.
All IHC stainings were performed on whole-tissue sections except for a few supplemental stains that were performed centrally on tissue microarrays (n = 55, n = 3, and n = 54 for Pax5, CD1a, and CD19, respectively). The scoring procedure was agreed on at a consensus meeting, and all the stainings were scored semiquantitatively by individual reference pathologists as negative, weak (<30% positive tumor cells or all tumor cells weakly positive), positive (>30% positive tumor cells), or not interpretable. The staining panel included CD20, CD79a, Pax5, CD19, CD10, immunoglobulin heavy chain m (IgM), CD3, CD1a, CD4, CD8, CD5, CD2 myeloperoxidase (MPO), TdT, and CD34. Owing to the retrospective nature of the study, the staining procedures and antibody sources for these markers varied between the participating countries and over time. As biopsy material obtained from the mediastinal tumors was often limited, the number of performed IHC stainings also varied from case to case.
A T-cell lineage was established on the basis of CD3 expression, a B-cell lineage by the expression of at least 2 of the following B-cell markers: CD19, CD79a, Pax5, and/or CD20, and a myeloid lineage by expression of MPO. Mixed lineage acute leukemia (MPAL) was diagnosed if the tumor cells fulfilled the diagnostic criteria for 2 lineages (Fig. 4 ). In accordance with the WHO classification, "bilineal" and "biphenotypical" diseases were not distinguished. Undifferentiated hematopoietic neoplasm (UHN) was diagnosed if a lineage could not be determined according to the above-mentioned criteria and after exclusion of other nonhematopoietic small round cell tumors.
Statistical Analysis
Fisher exact test was carried out using the Graph-Pad Prism software.
RESULTS
Diagnosis
As the clinical analysis of the Euro-LB 02 trial is not yet available, this study focuses on the pathology review. The clinical results will be published elsewhere. Overall data for 196 study patients were collected and reviewed by the panel. In 8 of the registered patients, the panel excluded the diagnosis of precursor cell lymphoma (3 diffuse large B-cell lymphomas, 1 Burkitt lymphoma, 2 mature aggressive B-cell lymphomas, and 2 unclassifiable lymphomas) due to insufficient immunostains, and these cases were excluded from all further analyses. In the remaining cohort (n = 188), the diagnostic categories of the WHO classification for precursor cell neoplasms were used. 26 The vast majority of LBL showed a typical morphology with monomorphic sheets of medium-sized blasts with round nuclei, finely dispersed nuclear chromatin, and a narrow rim of cytoplasm. However, in a small subset of cases (n = 3), we observed considerable morphologic variation ( Fig. 1 ).
In 146 cases, all stainings required for application of the criteria outlined in the Material and Methods section were evaluated. Of those, 42 (29%) were classified as precursor B-cell LBL (B-LBL), 90 (62%) as precursor T-cell LBL (T-LBL), 11 (7%) as MPAL, and 3 (2%) as UHN. A subset of confirmed precursor lymphomas (n = 42) showed markers of at least 1 lineage (36% B, 64% T), but the IHC panel was not complete to exclude any additional lineage differentiation.
T-LBL
Within the group of 90 T-LBLs, we initially attempted to distinguish the immunological maturation stages that are pro-T-LBL, pre-T-LBL, cortical T-LBL, and medullary/ mature T-LBL as defined by the European Group for the Immuno logical Characterization of Leukemias (EGIL) classification. 2 To apply this classification, it is necessary to distinguish between cytoplasmic and membranous CD3 staining for differentiation of early pro-T-LBL, pre-T-LBL, and medullary/mature T-LBL. However, the panel agreed that a distinction between cytoplasmic and membranous CD3 staining cannot be reliably made using IHC on FFPE specimens (Fig. 2 ). Thus, we could only distinguish 49 cortical T-LBLs (54%), which differed from all other subtypes in their expression of CD1a, and noncortical (n = 35, 39%) or unclassifiable T-LBLs that lacked sufficient IHC stainings for subtyping (n = 6, 7%). This percentage of cortical LBL in our study was comparable with previous publications. 6 To evaluate whether additional IHC stainings might help to distinguish early T-LBL (pro-T-LBL and pre-T-LBL) from later T-LBL (cortical and medullary/mature T-LBL), we assessed possible markers of early stages of T-cell differentiation (CD34, CD10, CD4/CD8 double negative) in cortical and noncortical T-LBLs. CD34 and CD10 were expressed in comparable fractions of cases in both the cortical and noncortical subtypes (12% vs. 23%, P = 0.3386 and 67% vs. 56%, P = 0.5314, respectively, Table 1 ). Cases expressing either CD4 or CD8 (single positive) were significantly more frequent in the group of noncortical T-LBL (42%) than in the group of cortical T-LBL (18%, P = 0.0354). As expected, cortical T-LBLs were more often double positive for CD4 and CD8 than noncortical T-LBL (78% vs. 36%, P = 0.0003), and showed a lower frequency of double negativity (4% vs. 23%, P = 0.284) ( Table 1 ).
B-LBL
Subtyping of B-LBL was performed according to the well-established categories of CD10 -/IgMpro-B-LBL was no difference in the subtype distribution in our series compared with a previously published large series of precursor pB-ALL (data not shown). 21 The majority of B-LBL was positive for CD79a. However, as CD79a might be expressed in a considerable number of T-LBLs and in accordance with the criteria of the WHO classification, we required a second positive B-cell marker to prove B-cell lineage differentiation. In addition, we determined the sensitivity and the specificity of B-cell markers in B-LBL. Of T-LBL samples, 12% (3 of 47, cortical and 6 of 33, noncortical, Table 2 ) were positive for CD79a, but none for any of the other B-cell markers (CD20, CD19, and Pax5). It should be noted that in CD79a + T-LBL, we also observed CD10 expression in 4 of 6 cases. The sensitivity of CD20 for the detection of the B-cell lineage in pLBL is poor (12 of 35, 34% positive), whereas the marker Pax5 was highly sensitive, with 35 of 35 (100%) of the analyzed B-LBL cases being positive.
MPAL
The group of MPAL consisted of 7 lymphomas with myeloid and B-cell lineage markers, 2 with myeloid and T-cell lineages, and 2 with B-cell and T-cell lineages ( Table 3 , Fig. 3 ). All MPALs were positive for TdT, but they expressed CD34 in only 5 of 10 cases that could be evaluated. All T-lineage MPALs were negative for CD1a (0 of 4) and CD56 (0 of 4).
UHN
Three cases were classified as UHN because they lacked any lineage-specific markers but expressed markers of immature hematopoietic cells such as TdT (1 of 3) or CD34 (2 of 3). Furthermore, less-specific hematopoietic markers were detected (Table 4 ) and other small round cell tumors were excluded, for example, by staining for CD56 (0 of 3, data not shown). Cases 1 and 3 presented as localized bone tumors in the lumbar spine and the iliac bone, respectively, whereas case 2 presented as a mediastinal tumor. Case 3 was initially misdiagnosed as Ewing sarcoma because of its strong CD99 positivity in the absence of the other main lineage markers and its suggestive localization within the bone.
TdT -LBL
TdT, the major marker of a precursor cell neoplasm in the B-cell and T-cell lineages, was expressed in 166 of 173 (96%) precursor cell neoplasms. Seven LBLs were diagnosed as TdT -LBLs, but all these lymphomas showed the typical morphology of LBL in addition to the immunophenotypic features of precursor cell neoplasms, such as weak or partial expression of TdT in 1% to 5% of the lymphoma cells (4 of 7), expression of CD34 (1 of 7), coexpression of CD3 and CD79a (1 of 7), or coexpression of CD4 and CD8 (1 of 7).
DISCUSSION
The new WHO lymphoma classification published in 2008 25 introduced several important changes in the field of B-precursor cell and T-precursor cell neoplasms: (i) the marker definition for determining the cell lineage was changed and the EGIL scoring system for biphenotypic leukemia 2 was abandoned, (ii) the terminology and definition of mixed phenotype precursor cell neoplasms was established, and (iii) subtypes defined by recurrent genetic aberrations were introduced. Most of our knowledge on the immunophenotypes of precursor cell neoplasms has been gathered from cases of leukemic disease by means of FC. Several of the current diagnostic criteria are difficult to apply on tissue specimens. The advantage of our study is that it points out the specific problems associated with the diagnosis of precursor cell neoplasms by means of histology and IHC on FFPE material. Biopsy material and consequently the number of feasible immunostains are often limited due to localization of the tumors. Therefore, we propose a well-reflected algorithm (Fig. 5 ) applicable for diagnosing and subtyping LBLs in daily practice. Using this algorithm, we identified T-LBL twice as often as B-LBL, which confirms previous reports. 6 The diagnosis of LBL should combine (i) typical morphology, (ii) proof of precursor cell immunophenotype, (iii) precise lineage definition, and (vi) subtyping by additional stainings and/or genetic analysis to obtain a final diagnosis. In our data, TdT expression is the most useful tool for confirming the precursor cell nature of a lymphoma. It should be used to stain all cases of LBL and other blastic neoplasms in children, as morphologic Pediatric Lymphoblastic Lymphomas variants of LBL may mimic other aggressive lymphomas, such as diffuse large B-cell lymphomas (Fig. 1) . Moreover, this staining can be helpful in the differential diagnosis of immature hematological neoplasms versus other small round blue cell tumors. However, it should be noted that rare nonhematopoietic tumors such as Merkel cell carcinomas may also express TdT. 3, 5, 24 In addition, TdT + bone marrow hematogones have to be considered when judging trephine specimens. 12 Similarly TdT + cortical thymocytes of a normal thymus should not be mistaken for T-LBL in small mediastinal biopsies. IHC staining for cytokeratin can be of help in such situations.
In the rare cases of TdT -LBL with otherwise typical lymphoblastic morphology, either expression of CD1a or CD34, coexpression of CD79a and CD3, or coexpression of CD4 and CD8 can be used to identify the precursor cell nature of the lymphoma. Coexpression of CD4 and CD8 has also been reported in cases of mature T-NHL, such as T-cell prolymphocytic leukemia and adult T-cell leukemia/lymphoma. 26 However, these entities are usually not a differential diagnosis in children. IHC stainings for CD3 and MPO are powerful tools for identifying the T-cell and myeloid lineages with a single staining for each lineage, according to the requirements of the WHO 2008 classification (Fig. 4) . Proof of the B-cell lineage requires at least 2 B-cell markers to be positive. We chose CD79a staining as the primary screening marker for 2 reasons. First, this is a widely known pan-B-cell marker that is accepted by the WHO and is also available in general pathology laboratories for rapid initial diagnosis in clinically urgent situations. Second, it isFas we showed in our seriesFa highly sensitive marker for detecting B-cell differentiation in LBLs and MPALs. Nevertheless, lineage assessment by means of CD79a alone would be hampered by its relatively low specificity, given the substantial proportion of CD79a coexpressing T-LBLs (12% in our series). Combination with a second B-cell marker is therefore mandatory. CD19 was found to be a highly sensitive and specific B-cell marker in our series. Pax5, a nuclear transcription factor involved in B-cell development, 7 has not yet been recommended by the WHO for lineage determination in ALL. Our data confirm very recent observations that Pax5 is a highly specific and sensitive B-cell marker within the context of LBLs. 15 Nevertheless, it has to be remembered that Pax5 has also been reported in rare nonhematopoietic neoplasms including tumors of the small round blue cell category. 13, 23 We thus recommend screening all cases of LBL with CD3, MPO, and CD79a and adding CD19 or Pax5 in CD79a + cases to confirm or rule out B-cell lineage differentiation (Fig. 5 ). The use of CD20 in the lineage determination of precursor cell neoplasms is of limited value, as the sensitivity of this marker is low in B-LBL. Recently, CD22 staining protocols for FFPE specimens were published and it may prove to be another useful marker for confirming B-cell lineage. 4 As T-LBL cases may coexpress CD79a and CD10, CD10 might be useful as a second marker for confirming B-cell lineage only in CD19 strongly positive B-LBL, as recommended by the WHO classification. 26 However, if CD79a was applied, the second line B-cell marker should be either Pax5 or CD19 (Fig. 5 ). It should also be noted that a precise quantification of the staining intensity of immune markers, as required for CD10 along with CD19 in the MPAL criteria of the WHO classification, cannot be reliably applied for IHC.
Although the criteria for lineage determination are now well defined by the WHO classification, immunophenotypical subtyping of the stage of differentiation in B-LBL and T-LBL is still based on the EGIL criteria and is widely used in ALL. 2 However, we faced several problems when we applied the proposed scheme for IHC staining on FFPE specimens. The subtyping of B-LBL is based on the expression of IgM and CD10. This can cause difficulties in cases in which reliable IgM staining cannot be achieved. Nevertheless, subtyping into the well-established categories used for ALL, namely CD10 -/ IgMpro-B-LBL, CD10 + /IgMcommon-B-LBL, and CD10 + /IgM + pre-B-LBL 2 was possible in B-LBL in our study when biopsy specimens of appropriate size are available. It should be stressed that TdT + pLBLs very rarely express surface immunoglobulin light chains. 10 The problems of subtyping according to the stage of differentiation are more pronounced in T-LBL, in which it is necessary to differentiate between cytoplasmic and membranous CD3 staining to distinguish pro-T-LBL and pre-T-LBL from medullary/mature T-LBL. 2 Although this is a standard procedure in FC, we did not find this distinction feasible for IHC on FFPE specimens. Nevertheless, the cortical subtype could be reliably differentiated from noncortical T-LBL on the basis of CD1a expression, a distinction that has been found clinically relevant in ALL. 6 Therefore, we suggest using CD1a staining to identify cortical T-LBL in daily practice and lumping all further subtypes (pro/pre-T-LBL and medullary/mature) together as noncortical T-LBL ( Fig. 5 ). It remains questionable whether the immunophenotypic subtypes of T-LBL defined by the EGIL criteria reflect a possible "cell of origin" accurately, as antigen expression in lymphomas may not precisely reflect the antigen expression pattern during T-cell development. 20 Being aware of the plasticity in thymic development, it is generally considered that CD8 + /CD4single positive T-LBL should derive from relatively mature thymocytes. However, we found CD34 expression, a marker indicating early T-cell precursors, in 2 of 6 CD8 + /CD4lymphomas that were analyzed (data not shown). In addition, unexpectedly, CD34 and CD10 expression was seen in roughly the same percentage in cortical and noncortical T-LBLs (Table 1) . Genetic analysis of T-cell receptor gene rearrangement, FC data, and results of molecular profiling can be expected to help identify new markers for distinguishing biologically relevant subtypes of T-LBLs in the future. Moreover, the possible clinical significance of CD34 expression in T-LBL should be evaluated in future studies. 27 Further new diagnostic markers might be obtained from molecular profiling, although the published series are rather small. 11, 18 Our study has several limitations. First, no genetic analysis was carried out. As the WHO classification uses several recurrent aberrations to delineate subtypes of B-ALL and MPAL, 14, 26 future studies on the cohort presented here will be valuable for studying these aberrations in LBL. Second, no clinical correlation could be made, as the results of the Euro-LB 02 trial have not been analyzed yet. Our cohort will be the basis for future studies investigating prognostic markers that have been described in T-ALL for their applicability in T-LBL 28 and for understanding the clinical relevance of multilineage differentiation in neoplasms that present clinically not as ALL 1 but as lymphomas.
We did not screen systematically for monocytic lineage differentiation, as recommended by the WHO. As discussed above, the WHO criteria were primarily designed for leukemias. Monocytic differentiation occurs frequently in acute myeloid leukemia, but may prove to be of lesser importance in diseases presenting as lymphomas. Nevertheless, we identified an unexpectedly large number of precursor cell neoplasms with mixed lineage marker expression within our cohort of lymphomas that were diagnosed and included in the trial primarily as LBLs (7%). In these MPALs, myeloid/B-cell differentiation seemed to be the most frequent phenotype, a finding that is comparable with data published for leukemias. 1, 29 Five of 10 cases tested were also positive for CD34. Unfortunately, we do not have the cytogenetic data on these cases, and therefore cannot exclude the possibility of myelosarcoma with t(8;21) in some of these cases. The prognostic relevance of this finding is still uncertain. However, MPALs presenting as leukemia have been reported to show a very aggressive clinical course in adults, 29 and also behaves more aggressively than pALL in children. 9 Our data indicate that systematic staining of precursor cell neoplasms for all 3 lineages (B-cell, T-cell, and myeloid) should be performed in every case even if a lineage differentiation has already been assigned to the disease by a limited staining panel. The staining algorithm that we propose for pediatric LBL will help to limit IHC stainings and to identify MPAL (Fig. 5 ). In the very rare cases of UHN that we observed, nonhematopoietic small round cell tumors should be carefully excluded and the staining panel for hematopoietic markers must be extended. It should be noted that CD99, a marker frequently used to identify Ewing sarcoma, may also be expressed in hematopoietic precursor cell neoplasms. Expression of CD56 in absence of other hematopoietic markers in tumors of the posterior mediastinum neuroblastoma has to be considered in the differential diagnosis.
